Eve Health (ASX:EVE) — Material Events
ASX:EVE · 21 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
EVE Health Secures Nextract, Advances Into $16B Pharma Markets with New ProductsHigh
EVE Health completes Nextract acquisition, raises $1M, advances pharmaceutical product rollout with regulatory and commercial milestones
31 July 2025
·Quarterly Activity and Appendix 4C
·85
EVE Unveils $30B Pipeline of Reformulated Sexual Health and Cardiovascular DrugsMedium
EVE completes reformulated drug R&D targeting $30B+ sexual health and cardiovascular markets, advancing patent filings and licensing strategy
10 Mar 2026
·Research and Development Update
·85
EVE Launches Dyspro™ Distribution via TeleDocs to Tackle Women’s Health MarketMedium
EVE launches Dyspro™ distribution for women's health with TeleDocs partnership
22 Sept 2025
·Product Launch Announcement
·85
EVE Health Group Launches Libbo™ and Digital Men’s Health Platform in AustraliaMedium
EVE Health Group launches Libbo™ and men's health digital platform in Australia
10 Feb 2026
·Product Launch Announcement
·80
EVE Health Group Secures $1.1M to Boost Dyspro and Libbo Market LaunchesMedium
EVE Health Group raises $1.1M to accelerate launches of Dyspro and Libbo
9 Oct 2025
·Capital Raising
·80
EVE Health Hits Key Milestones with Dyspro™ Prescriptions and Libbo™ ManufacturingMedium
EVE Health achieves first Dyspro™ prescriptions, completes Libbo™ manufacturing, and raises $1.1M to accelerate commercial rollout
30 Jan 2026
·Quarterly Activities and Cash Flow Report
·80
EVE Health Prescribes Dyspro™ to First Patients, Launches Support PlatformMedium
EVE Health's Dyspro™ prescribed to first patients; launches Reclaim My Cycle support platform
1 Oct 2025
·Product Launch Announcement
·80
EVE Health Launches Libbo Commercially and Expands Reformulation Pipeline with $1.3M RaiseMedium
EVE Health launches Libbo® commercially, expands pipeline, raises $1.3M
29 Apr 2026
·Quarterly Activities and Cash Flow Report
·80
EVE Health Launches Dyspro™ and Libbo™ with $1.1M Boost for Commercial RolloutMedium
EVE Health advances Dyspro™ and Libbo™ commercialization with $1.1M placement and first patient prescriptions
31 Oct 2025
·Quarterly Activities and Cashflow Report
·80
EVE Health Group Boosts Placement to $1.3M with Strategic Cornerstone InvestorMedium
EVE Health Group secures $1.3M placement with cornerstone investor boost for pharmaceutical reformulation programs
18 Mar 2026
·Capital Raising
·75
Eve Health Accelerates Fast-Acting Pharma with SAS-B Validation and Licensing DealsMedium
Eve Health advances fast-onset pharmaceutical products with SAS-B validation and partner-led commercialisation
26 Mar 2026
·Investor Presentation
·75
EVE Advances Men’s Health with Libbo™ Ready for Market LaunchMedium
EVE completes manufacturing and distribution of Libbo™ for imminent market launch
30 Jan 2026
·Product Launch Announcement
·75
EVE Health Clears Regulatory Path for Australian Launch of Libbo and DysproMedium
EVE Health clears regulatory hurdles for Australian launch of Libbo and Dyspro in 2025
21 July 2025
·Regulatory Update
·75
EVE Health Group Elevates Ben Rohr to CEO to Drive Commercial GrowthMedium
EVE Health Group appoints Ben Rohr as CEO, Damian Wood shifts to regulatory role
28 Apr 2026
·Executive Appointment
·70
EVE Health Group Launches $1.3M Capital Raise with Placement Shares and OptionsMedium
EVE Health Group launches $1.3M capital raise with Placement Shares and Options, subject to shareholder approval
20 Mar 2026
·Prospectus
·70
EVE Health Launches Nationwide Telehealth Support for Dyspro and Libbo PatientsMedium
EVE Health partners with hubMed for national telehealth patient support program
19 Nov 2025
·Major Contract Announcement
·70
EVE Health Group’s Revenue Slumps 19% Amid Rising Losses in FY2025Medium
EVE Health Group reports 19% revenue decline and increased net loss for FY2025
29 Aug 2025
·Appendix 4E - Results for Announcement to the Market
·70
EVE Health Group Raises $1.1M to Accelerate Launch of Dyspro and LibboMedium
EVE Health Group launches $1.1M placement to fund pharmaceutical product rollout
15 Oct 2025
·Prospectus
·70
EVE Launches Nationwide Telehealth Support for Dyspro and Libbo PatientsMedium
EVE partners with hubMed to launch national telehealth support program for Dyspro and Libbo patients
19 Nov 2025
·Major Contract Announcement
·70
EVE Health Group Secures $0.9M to Boost Drug Reformulation PipelineMedium
EVE Health Group Raises $0.9M to Advance Drug Reformulation Pipeline
13 Mar 2026
·Capital Raising
·70
EVE Health Taps Dr Fiona Cousins to Boost Women’s Health Pipeline Ahead of Dyspro™ LaunchMedium
EVE Health appoints Dr Fiona Cousins to Scientific Advisory Board ahead of Dyspro™ launch
15 Sept 2025
·Board Appointment
·65
No articles in this tier for the last 12 months.
Market Mentions
6
- appeared in market wrap coverage
These are market wrap articles where Eve Health (ASX:EVE) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Healthcare Wrap - Week 13 (23 Mar -> 27 Mar) 2026
28 Mar 2026
Healthcare Wrap - Week 12 (16 Mar -> 20 Mar) 2026
21 Mar 2026
Healthcare Wrap - Week 11 (9 Mar -> 13 Mar) 2026
14 Mar 2026
Healthcare Wrap - Week 7 (9 Feb -> 13 Feb) 2026
14 Feb 2026